Pharmacokinetics and pharmacodynamics of the triptan antimigraine agents: a comparative review

Clinical Pharmacokinetics
S S JheeN R Cutler

Abstract

The current approach to antimigraine therapy comprises potent serotonin 5-HT1B/1D receptor agonists collectively termed triptans. Sumatriptan was the first of these compounds to be developed, and offered improved efficacy and tolerability over ergot-derived compounds. The development of sumatriptan was quickly followed by a number of 'second generation' triptan compounds, characterised by improved pharmacokinetic properties and/or tolerability profiles. Triptans are believed to effect migraine relief by binding to serotonin (5-hydroxy-tryptamine) receptors in the brain, where they act to induce vasoconstriction of extracerebral blood vessels and also reduce neurogenic inflammation. Although the pharmacological mechanism of the triptans is similar, their pharmacokinetic properties are distinct. For example, bioavailability of oral formulations ranges between 14% (sumatriptan) and 74% (naratriptan), and their elimination half-life ranges from 2 hours (sumatriptan and rizatriptan) to 25 hours (frovatriptan). Clearly, such diverse pharmacokinetic properties will influence the effectiveness of the compounds and favour the prescription of one over another in different patient populations. This article reviews the pharmacological prop...Continue Reading

References

Oct 10, 1992·Lancet·F VachonG Charmot
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN Subcutaneous Sumatriptan International Study Group
Jan 1, 1991·European Neurology·P A FowlerN S Baber
Nov 1, 1991·British Journal of Clinical Pharmacology·A K ScottP A Fowler
Dec 1, 1991·Trends in Pharmacological Sciences·P P Humphrey, W Feniuk
Sep 28, 1991·Lancet·P J GoadsbyJ W Lance
Apr 1, 1995·Journal of Clinical Pharmacology·N R SrinivasR H Barbhaiya
Feb 1, 1995·Cephalalgia : an International Journal of Headache·C Wöber-BingölB Schuch
Jan 1, 1995·European Journal of Clinical Pharmacology·L F LaceyP A Fowler
Apr 1, 1995·Journal of Clinical Psychopharmacology·P Blier, R Bergeron
Nov 1, 1994·Clinical Pharmacokinetics·A K Scott
Jul 1, 1994·Headache·S D Silberstein
Apr 26, 1994·Proceedings of the National Academy of Sciences of the United States of America·G W RebeckM A Moskowitz
Apr 1, 1993·Trends in Pharmacological Sciences·M D Ferrari, P R Saxena
Feb 1, 1996·Cephalalgia : an International Journal of Headache·W J Meyler
Mar 1, 1996·British Journal of Clinical Pharmacology·R E Wojnar-HortonK F Ilett
Aug 1, 1996·QJM : Monthly Journal of the Association of Physicians·R J ScottG I McLaren
Dec 1, 1996·Cephalalgia : an International Journal of Headache·W H VisserM D Ferrari
May 1, 1997·Journal of Neurology, Neurosurgery, and Psychiatry·R E CullA Dunbar
May 1, 1997·Cephalalgia : an International Journal of Headache·H E ConnorP P Humphrey
Feb 12, 1998·British Journal of Clinical Pharmacology·R W PeckJ Posner
Feb 26, 1998·The Annals of Pharmacotherapy·D M Gardner, L D Lynd
May 28, 1998·Cephalalgia : an International Journal of Headache·M A BomhofH Hassani
Sep 2, 1998·Journal of Clinical Pharmacology·R DixonJ Rautureau
Oct 30, 1998·Cephalalgia : an International Journal of Headache·L YogendranP Winter
Nov 25, 1998·Cephalalgia : an International Journal of Headache·C G Dahlöf, N Mathew

❮ Previous
Next ❯

Citations

Oct 9, 2002·Pharmazie in unserer Zeit·Andreas Link, Britta Link
Jun 20, 2007·Pharmaceutical Research·Steven J SiegelTerri Sebree
Apr 22, 2005·The American Journal of Medicine·Ninan T Mathew, Elizabeth W Loder
Feb 20, 2004·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·E MoroG Frigo
Jun 1, 2005·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·A Femenía-FontA López-Castellano
May 1, 2010·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Mark W Pierce
Nov 22, 2002·Psychosomatics·Scott C Armstrong, Kelly L Cozza
Mar 15, 2005·Clinical Pharmacokinetics·Janet D McEnroe, Joseph C Fleishaker
May 29, 2014·Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·Gianni AllaisChiara Benedetto
Nov 3, 2006·Expert Review of Neurotherapeutics·Giorgio SandriniGiuseppe Nappi
May 1, 2009·Expert Review of Neurotherapeutics·Marcelo E BigalRichard Hargreaves
Mar 17, 2015·Expert Opinion on Drug Safety·János TajtiLászló Vécsei
Nov 26, 2009·Expert Opinion on Drug Metabolism & Toxicology·Giorgio SandriniGiuseppe Nappi
Dec 15, 2010·Expert Opinion on Drug Metabolism & Toxicology·Giovanna GentilePaolo Martelletti
Nov 30, 2002·Expert Opinion on Investigational Drugs·Hermann Mucke
Jul 7, 2007·Drug Development and Industrial Pharmacy·Kamal K UpadhyaySanjay K Jain
Apr 5, 2007·Current Medical Research and Opinion·Michele FisherDenise Shaw
Feb 28, 2003·Journal of Clinical Pharmacy and Therapeutics·A S W Boutilier, D M Gardner
Jun 15, 2016·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Robert S Foti, Deepak K Dalvie
Mar 20, 2004·Cephalalgia : an International Journal of Headache·J R BaldwinB J Carel
Dec 18, 2013·Cephalalgia : an International Journal of Headache·Elizabeth Loder, Emma Weizenbaum
Oct 28, 2015·Cephalalgia : an International Journal of Headache·Anne Francke ChristensenJes Olesen
Jan 24, 2006·Cephalalgia : an International Journal of Headache·C G H Dahlöf
Nov 17, 2010·Cephalalgia : an International Journal of Headache·Jeffrey L SeeburgerKathryn M Connor
Sep 2, 2016·Therapeutic Advances in Neurological Disorders·Matilde CapiPaolo Martelletti
Dec 15, 2004·Cephalalgia : an International Journal of Headache·A Gendolla
Dec 15, 2004·Cephalalgia : an International Journal of Headache·Rm Gallagher
Jul 9, 2002·Cephalalgia : an International Journal of Headache·J van der PostJ M A van Gerven
May 25, 2002·Headache·Alan RapoportCharlotte Keywood
Oct 9, 2002·Pharmazie in unserer Zeit·Marion Gurrath
Sep 3, 2004·Journal of Clinical Pharmacology·Arthur H ElkindGary Ishkanian
Oct 12, 2018·Journal of Clinical Psychopharmacology·Richard I Shader, David J Greenblatt

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved